background
caus
declar
global
pandem
treatment
guidelin
vari
countri
yet
approv
therapeut
includ
search
term
includ
combin
covid
glucocorticoid
convalesc
plasma
antivir
antibacteri
restrict
type
studi
design
elig
inclus
march
initi
manuscript
identifi
articl
fortyon
studi
includ
clinic
trial
case
report
case
seri
retrospect
prospect
observ
studi
thirtysix
studi
conduct
china
common
mention
report
medicin
systemat
review
corticosteroid
follow
lopinavir
oseltamivir
systemat
review
protocol
develop
base
prismap
prisma
statement
articl
review
select
electron
databas
embas
medlin
googl
scholar
readili
access
peerreview
full
articl
english
publish
decemb
st
march
th
includ
search
term
includ
combin
glucocorticoid
chloroquin
convalesc
plasma
antivir
antibacteri
oseltamivir
hydroxychloroquin
chloroquin
phosphat
monoclon
antibodi
restrict
type
studi
design
elig
inclus
howev
like
quantit
rct
articl
focu
review
therapeut
use
manag
patient
primari
outcom
evid
therapeut
use
manag
patient
clinic
practic
sinc
emerg
outbreak
irrespect
patient
characterist
set
outcom
measur
discuss
common
report
medicin
review
clinic
outcom
therapeut
treatment
recoveri
mortal
patient
secondari
outcom
advers
event
associ
treatment
duplic
articl
remov
titl
independ
screen
review
abstract
follow
full
articl
review
doubt
remain
inclus
exclus
record
follow
prisma
guidelin
present
form
prisma
flow
diagram
detail
reason
record
exclus
critic
apprais
checklist
appropri
studi
design
appli
check
second
team
member
bia
qualiti
issu
identifi
consid
prior
quantit
metaanalysi
metanarr
cap
apprais
checklist
tool
use
qualiti
assess
data
extract
tool
design
captur
focu
interest
popul
geograph
locat
methodolog
specif
mention
therapeut
treatment
advers
event
key
find
research
ethic
review
requir
review
exist
peer
review
literatur
march
initi
manuscript
identifi
articl
inclus
exclus
report
follow
prisma
guidelin
present
form
prisma
flow
diagram
figur
reason
exclus
record
tabl
follow
duplic
remov
record
duplic
remov
record
exclud
exclud
languag
chines
dutch
vietnames
italian
russian
portugues
iranian
german
ten
reason
includ
incomplet
irrelev
articl
consensu
final
inclus
studi
negoti
without
need
third
review
present
tabl
fortyon
studi
includ
clinic
trial
case
report
case
seri
retrospect
prospect
observ
studi
thirtysix
studi
conduct
china
korea
usa
franc
singapor
macau
total
number
patient
report
studi
male
femal
unspecifi
mean
age
year
studi
age
specifi
three
studi
common
report
medicin
systemat
review
antiinflammatori
medic
corticosteroid
differ
name
product
characterist
corticosteroid
methylprednisolon
dexamethason
follow
antivir
hiv
medic
lopinavir
combin
lopinavir
ritonavir
alon
follow
oseltamivir
arbidol
hydrochlorid
term
antibacteri
medicin
moxifloxacin
tigecyclin
report
convalesc
plasma
therapi
report
one
multi
center
retrospect
observ
studi
patient
outcom
therapeut
given
vari
patient
discharg
recoveri
ongo
hospit
mortal
avail
data
concern
issu
shown
tabl
first
date
review
relat
therapeut
use
covidpati
systemat
manner
march
twentysixth
sinc
emerg
fortyon
research
articl
therapeut
found
elig
includ
current
systemat
review
three
clinic
trial
either
case
report
case
seri
prospect
retrospect
observ
studi
systemat
corticosteroid
differ
name
formul
commonli
mention
use
medic
follow
antivir
lopinavir
oseltamivir
arbidol
hydrochlorid
convalesc
plasma
therapi
mention
one
multicent
retrospect
observ
studi
administ
six
patient
abidol
hydrochlorid
fourth
mention
medicin
review
broadspectrum
inhibitor
influenza
b
viru
parainfluenza
viru
type
virus
includ
hepat
c
viru
use
russia
china
yet
approv
use
countri
howev
conclus
evid
efficaci
report
review
report
togeth
favipiravir
approv
recent
treatment
novel
influenza
februari
china
chloroquin
phosphat
hydroxychloroquin
report
review
show
favor
outcom
recoveri
patient
mechan
action
virus
two
medicin
probabl
effect
chloroquin
use
long
time
treat
malaria
show
posit
outcom
patient
furthermor
hydroxychloroquin
show
signific
effect
kill
intracellar
pathogen
coxiella
burnetii
agent
q
fever
french
open
label
nonrandom
clinic
trial
promis
first
clinic
trial
medic
patient
effect
hydroxychloroquin
signific
show
reduct
viral
load
compar
control
group
moreov
effect
hydroxychloroquin
significantli
effect
azithromycin
ad
patient
accord
clinic
need
howev
clinic
followup
occurr
advers
effect
discuss
paper
work
done
medicin
reduc
spread
although
two
medicin
shown
promis
activ
risk
arrhythmia
associ
requir
caution
use
higher
cumul
dosag
therefor
recommend
use
suspectedconfirm
restrict
hospit
patient
march
issu
emerg
use
author
chloroquin
hydroxychloroquin
treat
patient
hospit
convalesc
plasma
treatment
mention
review
multicent
cohort
research
critic
ill
patient
admit
icu
wuhan
find
show
convalesc
plasma
administ
six
patient
transfus
reaction
occur
howev
studi
could
provid
adequ
inform
efficaci
convalesc
plasma
due
limit
sampl
size
lack
random
control
group
fact
convalesc
plasma
therapi
could
promis
method
treatment
patient
recent
studi
conduct
china
case
seri
show
five
critic
ill
patient
laboratori
confirm
acut
respiratori
distress
syndrom
bodi
temperatur
normal
within
day
patient
receiv
plasma
transfus
recov
patient
viral
load
also
decreas
becam
neg
within
day
transfus
patient
discharg
hospit
stabl
condit
day
transfus
march
us
fda
approv
convalesc
plasma
treatment
investig
use
tradit
investig
new
drug
applic
ind
regulatori
pathway
elig
patient
confirm
sever
immedi
lifethreaten
condit
respiratori
failur
septic
shock
andor
multipl
organ
dysfunct
failur
notabl
potenti
risk
ethic
issu
associ
use
includ
increas
thrombot
event
risk
occur
administr
date
lack
high
qualiti
research
particular
area
select
donor
high
neutral
antibodi
titer
first
systemat
review
date
relat
therapeut
use
patient
research
articl
therapeut
found
elig
includ
conduct
china
three
clinic
trial
antiinflammatori
medic
corticosteroid
found
mention
use
medicin
studi
despit
safeti
alert
made
cdc
follow
antivir
medic
lopinavir
oseltamivir
arbidol
hydrochlorid
although
research
warrant
amount
evid
increas
limit
avail
data
studi
present
current
pictur
treatment
modal
use
propel
develop
treatment
need
character
futur
studi
n
g
w
c
q
q
n
l
w
n
g
x
c
h
e
n
g
z
p
n
e
l
c
l
n
c
l
c
h
r
c
e
r
c
n
g
n
g
n
f
e
n
f
h
e
n
v
e
l
c
r
n
v
r
u
e
e
c
v
u
l
c
e
n
e
r
u
n
w
e
n
z
h
u
c
z
h
e
j
n
g
c
h
n
p
u
b
l
h
e
n
l
n
e
h
e
f
p
r
n
f
e
b
j
n
f
e
c
h
p
r
g
c
e
n
c
b
w
n
g
w
e
n
e
l
r
l
f
l
p
n
v
r
r
n
v
r
n
u
l
h
p
l
z
e
w
h
e
v
e
r
e
c
v
h
e
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
n
g
e
e
n
f
e
v
e
r
e
c
u
e
r
e
p
r
r
n
f
e
c
n
r
w
h
e
n
c
v
e
e
u
p
e
c
e
n
e
r
g
u
n
c
e
r
f
r
w
h
w
e
b
e
c
c
e
e
r
h
p
w
w
w
w
h
n
p
u
b
l
c
n
e
l
c
l
n
c
l
n
g
e
e
n
f
e
v
e
r
e
c
u
e
r
e
p
r
r
n
f
e
c
n
w
h
e
n
n
v
e
l
c
r
n
v
r
u
n
c
v
n
f
e
c
n
u
p
e
c
e
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
sekhar
virtual
screen
bade
predict
potenti
drug
therapeut
data
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
epidem
associ
event
around
world
centuri
gi
technolog
support
global
fight
outbreak
epidem
zeng
q
et
al
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
taiwan
ye
therapeut
data
velavan
meyer
c
epidem
ye
commentari
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
patient
receiv
intervent
die
lopinavirritonavir
develop
gastrointestin
advers
event
includ
anorexia
nausea
abdomin
discomfort
diarrhea
well
two
seriou
advers
event
acut
gastriti
two
recipi
selflimit
skin
erupt
studi
address
focus
issu
random
done
intent
treat
analysi
popul
enter
studi
properli
account
conclus
blind
done
group
enter
studi
similar
togeth
treat
equal
primari
outcom
clearli
specifi
one
patient
stop
treatment
postinclus
nausea
clinic
followup
occurr
sideeffect
discuss
paper
guan
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
case
report
assur
posit
impact
patient
health
due
medic
taken
need
random
control
trial
done
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
one
case
studi
repres
whole
popul
patient
refus
ventil
support
intens
care
unit
repeatedli
suffer
claustrophobia
therefor
receiv
highflow
nasal
cannula
need
random
control
trial
done
report
due
exploratori
natur
studi
driven
formal
hypothes
sampl
size
calcul
waiv
research
acknowledg
specif
inform
icu
miss
mechan
ventil
set
studi
includ
drug
dose
frequenc
durat
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
studi
done
one
set
inform
hospit
capabl
personnel
equip
mortal
rate
centr
littl
higher
centr
tradit
chines
medicin
given
studi
includ
drug
dose
frequenc
durat
studi
includ
drug
dose
frequenc
durat
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
meta
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
